Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ADC Therapeutics (ADCT) Enterprise Value (2019 - 2026)

ADC Therapeutics has reported Enterprise Value over the past 8 years, most recently at -$231.0 million for Q1 2026.

  • Quarterly results put Enterprise Value at -$231.0 million for Q1 2026, down 18.65% from a year ago — trailing twelve months through Mar 2026 was -$231.0 million (down 18.65% YoY), and the annual figure for FY2025 was -$261.3 million, down 4.17%.
  • Enterprise Value reached -$231.0 million in Q1 2026 per ADCT's latest filing, up from -$261.3 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$326441.0 in Q3 2023 and bottomed at -$310.5 million in Q1 2023.
  • Median Enterprise Value over the past 5 years was -$234.7 million (2025), compared with a mean of -$184.4 million.
  • The largest annual shift saw Enterprise Value skyrocketed 99.91% in 2022 before it plummeted 86257.23% in 2024.
  • Over 5 years, Enterprise Value stood at -$298.3 million in 2022, then rose by 6.6% to -$278.6 million in 2023, then grew by 9.95% to -$250.9 million in 2024, then decreased by 4.17% to -$261.3 million in 2025, then increased by 11.61% to -$231.0 million in 2026.
  • Business Quant data shows Enterprise Value for ADCT at -$231.0 million in Q1 2026, -$261.3 million in Q4 2025, and -$234.7 million in Q3 2025.